复方卡森糖浆缓解D-氨基半乳糖引起的小鼠急性化学性肝损伤

doi:10.12300/j.issn.1674-5817.2021.140

实验动物与比较医学 ›› 2022, Vol. 42 ›› Issue (3): 194-200.DOI: 10.12300/j.issn.1674-5817.2021.140

复方卡森糖浆缓解D-氨基半乳糖引起的小鼠急性化学性肝损伤

麦丽开·阿不力米提¹()(), 艾山·艾比布勒¹, 史深¹, 阿不都沙拉木·阿不都热依木², 艾尼瓦尔·塔力甫³

^1.新疆维吾尔自治区疾病预防控制中心, 乌鲁木齐 830002
^2.新疆维吾尔自治区中医医院老年病科, 乌鲁木齐 830000
^3.新疆维吾尔自治区维吾尔医院, 乌鲁木齐 830000

收稿日期:2021-03-16 修回日期:2021-07-21 出版日期:2022-06-25 发布日期:2022-07-01
作者简介:麦丽开· 阿不力米提（1977—），女，高级实验师，研究方向：从事实验动物研究。E-mail：928312699@qq.com。ORCID：0000-0003-0875-1477
艾尼瓦尔· 塔力甫（1973—），男，博士，主任医师，研究方向：药物临床试验研究。E-mail：154914729@qq.com
基金资助:
少数民族科技人才特殊培养计划科研项目：复方卡森糖浆对化学性及免疫性肝损伤的保护作用研究(2017D03009)

Compound Casson Syrup Alleviates Acute Chemical Liver Injury in Mice Caused by D-galactosamine

·Ablimiti Merika¹()(), ·Abibule Aishan¹, Shen SHI¹, ·Abdu-reyimu Abdu-salamu², ··Taleb Enivar³

^1.Xinjiang Center for Disease Control and Prevention, Urumqi 830002, China
^2.Department of Geriatrics, Xinjiang Hospital of Traditional Chinese Medicine, Urumqi 830000, China
^3.Xinjiang Uyghur Hospital, Urumqi 830000, China

Received:2021-03-16 Revised:2021-07-21 Published:2022-06-25 Online:2022-07-01

摘要/Abstract

摘要：

目的探讨复方卡森糖浆对D-氨基半乳糖（D-galactose）致小鼠急性化学性肝损伤的保护作用。方法通过腹腔注射D-氨基半乳糖800 mg/kg建立小鼠化学性肝损伤模型。根据服用药物及剂量不同分为模型对照组（不服用药物），复方卡森糖浆低剂量组、中剂量组、高剂量组，炎消迪娜儿糖浆阳性对照组，同时设立正常对照组。每组8只。复方卡森糖浆（8 mL·kg^-1·d^-1）与炎消迪娜儿糖浆（12 mL·kg^-1·d^-1）分别灌胃后，检测小鼠血清生化、肝功能及肝损伤免疫学指标的变化，并通过HE染色观察肝组织病理性改变。结果与正常对照组相比，模型组小鼠肝脏指数升高（P＜0.05），提示肝损伤。与模型组比较，复方卡森糖浆治疗后血清生化、肝功能指标均有所下降（P＜0.05）。与对照组比较，模型组小鼠肝脏匀浆中丙二醛（malondialdehyde，MDA）和谷胱甘肽过氧化物酶（glutathione peroxidase，GSH-Px）活性增高（P＜0.05），超氧化物歧化酶（superoxide dismutase，SOD）活性明显降低（P＜0.01）。与模型组比较，复方卡森糖浆各剂量组小鼠SOD活性均升高（P＜0.05）。HE染色结果显示，复方卡森糖浆组的小鼠肝脏炎性细胞浸润、变性、坏死等肝损伤病理现象有所改善。结论复方卡森糖浆能有效缓解D-氨基半乳糖诱导的小鼠肝损伤状态，对肝脏有一定的保护作用。

关键词: 复方卡森糖浆, 急性化学性肝损伤, 保肝作用, 小鼠

Abstract:

Objective To investigate the protective effect of compound Casson syrup on acute chemical liver injury induced by D-galactose in mice.Methods The chemical liver injury model was established by intraperitoneal injection of D-galactose 800 mg/kg. The experiment was divided into 6 groups, including normal control group, model control group, positive control group of Yanxiaodinar syrup, and compound Casson syrup low-dose, medium-dose and high-dose groups, with 8 rats in each group. After intragastric administration of compound Casson syrup (8 mL·kg^-1·d^-1) and Yanchaudinar syrup (12 mL·kg^-1·d^-1), the changes of serum biochemistry, liver function and immunological indexes of liver injury were detected, and the pathological changes of liver tissue were observed.Results Compared with the normal control group, the liver index of model group was increased (P < 0.05), suggesting liver injury. Compared with model group, serum biochemical and liver function indexes were decreased after treatment with compound Casson syrup (P < 0.05). Compared with normal control group, the activities of malondialdehyde (MDA) and glutathione peroxidase (GSH-Px) in liver homogenate of model group were increased (P < 0.05), and the activity of superoxide dismutase (SOD) was significantly decreased (P < 0.01). Compared with model group, SOD activity in compound Casson syrup groups was increased (P < 0.05). HE staining showed the inflammatory cell infiltration, degeneration, necrosis and other pathological phenomena of mouse liver caused by D-galactose were reversed after Casson syrup treatment.Conclusion Compound Casson syrup can effectively relieve the liver injury induced by D-galactose, and has a certain protective effect on liver.

Key words: Compound Casson syrup, Acute chemical liver injury, Liver protection, Mice

中图分类号:

R-332

麦丽开·阿不力米提, 艾山·艾比布勒, 史深, 阿不都沙拉木·阿不都热依木, 艾尼瓦尔·塔力甫. 复方卡森糖浆缓解D-氨基半乳糖引起的小鼠急性化学性肝损伤[J]. 实验动物与比较医学, 2022, 42(3): 194-200.

·Ablimiti Merika, ·Abibule Aishan, Shen SHI, ·Abdu-reyimu Abdu-salamu, ··Taleb Enivar. Compound Casson Syrup Alleviates Acute Chemical Liver Injury in Mice Caused by D-galactosamine[J]. Laboratory Animal and Comparative Medicine, 2022, 42(3): 194-200.

图/表 4

参考文献 16

1	代云云, 谢晓蓉, 王茂鹤, 等. 我国四大民族医药体系概述[J]. 中华中医药杂志, 2021, 36(3):1522-1525.
	DAI Y Y, XIE X R, WANG M H, et al. Overview of four national medicine system[J]. China J Tradit Chin Med Pharm, 2021, 36(3):1522-1525.
2	刘燕, 张莉, 黄华. 具抗炎作用维药的研究进展[J]. 中国中药杂志, 2014, 39(9):1714-1720. DOI:10.4268/cjcmm20140933 .
	LIU Y, ZHANG L, HUANG H. Advance in studies on anti-inflammatory effect of Uygur medicine[J]. China J Chin Mater Med, 2014, 39(9):1714-1720. DOI:10.4268/cjcmm20140933 .
3	张晓恒, 姚佳, 秦冬梅. 毛菊苣提取物对小鼠肝纤维化的保护作用[J]. 世界华人消化杂志, 2020, 28(3):86-91.
	ZHANG X H, YAO J, QIN D M. Protective effects of Cichorium glandulosum Boiss extracts against liver fibrosis in mice[J]. World Chin J Dig, 2020, 28(3):86-91.
4	阿吉艾克拜尔·艾萨, 信学雷, 吴涛, 等. 毛菊苣功能成分及药理作用研究[Z]. 国家科技成果, 2017.
	Aji-Ekbel·Isa, XIN X L, WU T, et al. Study on functional constituents and pharmacological effects of Chicory hairy [Z]. National Scientific and Technological Achievements, 2017.
5	吴晓琴, 宋晓琳, 彭瀛, 等. 花脸蘑多糖水提取物对D-氨基半乳糖致小鼠急性肝损伤的保护作用[J]. 延边大学医学学报, 2013, 36(1):22-24. DOI:10.16068/j.1000-1824.2013.01.005 .
	WU X Q, SONG X L, PENG Y, et al. Protective effects of water extract of the Lepista sordida polysaccharides for D-galactosamine-induced acute liver injury in mice[J]. J Med Sci Yanbian Univ, 2013, 36(1):22-24. DOI:10.16068/j.1000-1824.2013.01.005 .
6	信学雷, 吴汉夔, 吕俏莹, 等. 维吾尔药毛菊苣提取物降糖活性的研究[J]. 天然产物研究与开发, 2012, 24(2):234-238. DOI:10.16333/j.1001-6880.2012.02.024 .
	XIN X L, WU H K, LV Q Y, et al. Hypoglycemic effect of extracts from Cichorium glandulosum [J]. Nat Prod Res Dev, 2012, 24(2):234-238. DOI:10.16333/j.1001-6880.2012.02.024 .
7	古力米拉·买买提衣明, 古力那孜·阿不都热合满. 维药清热卡森颗粒治疗脂肪肝61例观察[J]. 中国民族医药杂志, 2014, 20(1):12-13. DOI:10.16041/j.cnki.cn15-1175.2014.01.011 .
	Gulimila·Maimaitiyiming, Reheman Gulinaz·Abudu. Obser-vation on 61 cases of fatty liver treated with weiqingre Casson Granule[J]. J Med Pharm Chin Minor, 2014, 20(1):12-13. DOI:10.16041/j.cnki.cn15-1175.2014.01.011 .
8	王晓杰, 吾买尔江·牙合甫, 阿丽米热·买买提, 等. 菊苣多糖对小鼠药物性肝损伤保护作用的筛选[J]. 现代畜牧兽医, 2021(4):9-13.
	WANG X J, Yakup·Omar, Mamat·Almira, et al. Screening of the protective effect of Cichorium intybus L.polysaccharide on drug-induced liver injury[J]. Mod J Animal Husb Vet Med, 2021(4):9-13.
9	秦冬梅, 胡利萍, 文志萍, 等. 维药毛菊苣提取物对小鼠四氮化碳急性肝损伤的保护作用[J]. 中国药理学通报, 2012, 28(8):1180-1181. DOI:10.3969/j.issn.1001-1978.2012.08.032 .
	QIN D M, HU L P, WEN Z P, et al. Protective effects of Cichorium glandulosum Boiss extracts on experimental liver injury in mice[J]. Chin Pharmacol Bull, 2012, 28(8):1180-1181. DOI:10.3969/j.issn.1001-1978.2012.08.032 .
10	张权林, 罗玉琴, 杨伟俊, 等. 刺山柑胶囊对肝损伤模型小鼠的保护作用及对大鼠胆汁分泌的影响[J]. 中国药房, 2014, 25(19):1747-1750. DOI:10.6039/j.issn.1001-0408.2014.19.06 .
	ZHANG Q L, LUO Y Q, YANG W J, et al. Protective effects of caper capsules on liver injury model mice and bile secretion of rats[J]. China Pharm, 2014, 25(19):1747-1750. DOI:10.6039/j.issn.1001-0408.2014.19.06 .
11	万晓莉, 谢笑龙, 刘杰, 等. 口服齐墩果酸对D-氨基半乳糖致小鼠急性肝损伤的保护作用[J]. 华西药学杂志, 2016, 31(1):26-29. DOI:10.13375/j.cnki.wcjps.2016.01.008 .
	WAN X L, XIE X L, LIU J, et al. Hepatoprotective effect of oleanolic acid on D-galactosamine- induced acute liver injury in the mice[J]. West China J Pharm Sci, 2016, 31(1):26-29. DOI:10.13375/j.cnki.wcjps.2016.01.008 .
12	中华人民共和国卫生部药典委员会. 中华人民共和国卫生部药品标准: 维吾尔药分册 [S]. 乌鲁木齐: 新疆科技卫生出版社, 1998:157.
	Pharmacopoeia Committee of the Ministry of Health of the People's Republic of China. Drug Standards of the Ministry of Health of the People's Republic of China: Uygur medicine volume [S]. Urumqi: Xinjiang People's Medical Publishing House, 1998:157.
13	代小佩. 我国病毒性肝炎发病率下降其他类型肝炎有所上升[N]. 科技日报, 2021-07-29(2).
	DAI X P. The incidence of viral hepatitis decreased and other types of hepatitis increased in China[N]. Science and Technology Daily, 2021-07-29(2).
14	熊亚茹, 张莹莹, 崔鲁炜, 等. 某复方口服液对小鼠酒精性肝损伤的辅助保护作用研究[J]. 预防医学情报杂志, 2021, 37(8):1164-1167.
	XIONG Y R, ZHANG Y Y, CUI L W, et al. Auxiliary protection of A compound oral liquid on alcoholic liver injury in mice[J]. J Prev Med Inf, 2021, 37(8):1164-1167.
15	付双楠, 朱平生, 高达. 中医药防治化学性肝损伤的研究进展[J]. 中医学报, 2017, 32(3):449-454. DOI:10.16368/j.issn.1674-8999.2017.03.116 .
	FU S N, ZHU P S, GAO D. Progress of TCM studies in TCM treatment of liver injury due to chemical factors[J]. Acta Chin Med, 2017, 32(3):449-454. DOI:10.16368/j.issn.1674-8999.2017.03.116 .
16	CHEN M J, VIJAY V, SHI Q, et al. FDA-approved drug labeling for the study of drug-induced liver injury[J]. Drug Discov Today, 2011, 16(15-16):697-703. DOI:10.1016/j.drudis.2011.05.007 .

组别 Group	剂量 Dose/(mL·kg^-1·d^-1)	实验前体质量 Pre-test body mass/g	解剖前体质量 Preanatomic body mass/g	肝脏指数 Liver index/ (mg·g^-1)	脾脏指数 Spleen index/ (mg·g^-1)
正常对照 Normal control	-	24.00±1.07	29.19±1.70	4.95±0.61	0.30±0.07
模型对照 Model control	-	25.00±2.39	28.85±4.88	5.93±0.84^*	0.36±0.01
炎消迪娜儿糖浆对照 YS control	12	20.13±3.31	27.16±2.98	4.42±0.75^#	0.32±0.05
低剂量复方卡森糖浆 Low-dose of CCS	4	27.50±0.76	30.99±1.36	4.50±0.38	0.26±0.05^#
中剂量复方卡森糖浆 Medium-dose of CCS	8	22.88±3.36	28.91±1.75	5.35±0.83	0.28±0.06^#
高剂量复方卡森糖浆 High-dose of CCS	16	26.13±0.99	28.66±1.81	4.64±0.29	0.32±0.06

组别 Group	剂量 Dose/(mL·kg^-1·d^-1)	实验前体质量 Pre-test body mass/g	解剖前体质量 Preanatomic body mass/g	肝脏指数 Liver index/ (mg·g^-1)	脾脏指数 Spleen index/ (mg·g^-1)
正常对照 Normal control	-	24.00±1.07	29.19±1.70	4.95±0.61	0.30±0.07
模型对照 Model control	-	25.00±2.39	28.85±4.88	5.93±0.84^*	0.36±0.01
炎消迪娜儿糖浆对照 YS control	12	20.13±3.31	27.16±2.98	4.42±0.75^#	0.32±0.05
低剂量复方卡森糖浆 Low-dose of CCS	4	27.50±0.76	30.99±1.36	4.50±0.38	0.26±0.05^#
中剂量复方卡森糖浆 Medium-dose of CCS	8	22.88±3.36	28.91±1.75	5.35±0.83	0.28±0.06^#
高剂量复方卡森糖浆 High-dose of CCS	16	26.13±0.99	28.66±1.81	4.64±0.29	0.32±0.06

组别 Group	剂量 Dose/(mL·kg^-1·d^-1)	ALT z/(U·L^-1)	AST z/(U·L^-1)	AST/ALT	ALP z/(U·L^-1)
正常对照 Normal control	-	34.63±1.41	144.50±27.30	4.18±0.84^#	171.50±20.10^#
模型对照 Model control	-	101.13±51.3^*	241.25±41.04^*	2.39±1.69	217.50±81.39^*
炎消迪娜儿糖浆对照 YS control	12	53.60±10.43	216.20±50.45	4.19±1.47	157.80±17.30^#
低剂量复方卡森糖浆 Low-dose of CCS	4	59.63±37.74	182.63±56.29	3.44±0.99	169.13±28.98^#
中剂量复方卡森糖浆 Medium-dose of CCS	8	45.25±17.80	159.13±31.84	3.79±0.95	173.38±27.64^#
高剂量复方卡森糖浆 High-dose of CCS	16	38.80±4.76	145.80±13.03	3.83±0.75	149.60±24.81^#

组别 Group	剂量 Dose/(mL·kg^-1·d^-1)	ALT z/(U·L^-1)	AST z/(U·L^-1)	AST/ALT	ALP z/(U·L^-1)
正常对照 Normal control	-	34.63±1.41	144.50±27.30	4.18±0.84^#	171.50±20.10^#
模型对照 Model control	-	101.13±51.3^*	241.25±41.04^*	2.39±1.69	217.50±81.39^*
炎消迪娜儿糖浆对照 YS control	12	53.60±10.43	216.20±50.45	4.19±1.47	157.80±17.30^#
低剂量复方卡森糖浆 Low-dose of CCS	4	59.63±37.74	182.63±56.29	3.44±0.99	169.13±28.98^#
中剂量复方卡森糖浆 Medium-dose of CCS	8	45.25±17.80	159.13±31.84	3.79±0.95	173.38±27.64^#
高剂量复方卡森糖浆 High-dose of CCS	16	38.80±4.76	145.80±13.03	3.83±0.75	149.60±24.81^#

[1]	梁敏, 郭洋, 王津津, 朱梦妍, 池骏, 陈艳娟, 王成稷, 喻智澜, 沈如凌. Dmd基因突变小鼠构建及在肌肉及免疫系统的表型验证[J]. 实验动物与比较医学, 2024, 44(1): 42-51.
[2]	郑建华, 法云智, 董巧燕, 邱业峰, 陈菁青. 高原急性缺氧肠道应激损伤小鼠模型的构建与评价[J]. 实验动物与比较医学, 2024, 44(1): 31-41.
[3]	唐倩倩, 张秀莉, 常在. 清华大学实验动物中心小鼠自动饮水系统漏水情况统计分析[J]. 实验动物与比较医学, 2024, 44(1): 85-91.
[4]	刘欣, 石少波, 张翠, 杨波, 曲川. 小鼠自体动静脉内瘘端侧吻合模型的建立与评价[J]. 实验动物与比较医学, 2023, 43(6): 595-603.
[5]	王丹, 张晓璐, 王妍, 傅博, 王文栋, 刘京, 张甦寅, 武怡荷, 吴德国, 杜小燕, 战大伟, 章秀林, 李长龙. Big-BALB/c小鼠亚系选育前后的抗体制备效率比较研究[J]. 实验动物与比较医学, 2023, 43(6): 612-618.
[6]	聂永强, 王朝霞. 濒危基因编辑小鼠品系拯救技术及其应用探讨[J]. 实验动物与比较医学, 2023, 43(6): 636-640.
[7]	于灵芝, 谢建芸, 冯丽萍, 魏晓锋. 金黄色葡萄球菌荧光定量PCR检测方法的建立及其在大鼠、小鼠粪便检测中的应用[J]. 实验动物与比较医学, 2023, 43(5): 566-573.
[8]	王成稷, 王珏, 王海杰, 陆炜晟, 史岩, 顾正页, 万鸣秋, 沈如凌. 乳胶血管灌注技术制作小鼠头面部静脉血管模型方法初探[J]. 实验动物与比较医学, 2023, 43(5): 574-578.
[9]	翟珊珊, 梁亮, 曹颖颖, 李竹欣, 王青, 陶俊宇, 运晨霞, 冷静, 唐海波. 一例树鼩毛发上皮瘤的诊断及细胞生物学特性观察[J]. 实验动物与比较医学, 2023, 43(4): 440-445.
[10]	黄缨, 韦思羽, 蔡莉, 强苏静, 李冬婷, 丁玉强. 供应商来源的实验大鼠和小鼠微生物监测结果分析：以复旦大学实验动物科学部为例[J]. 实验动物与比较医学, 2023, 43(4): 347-354.
[11]	谈小倩, 杨颢, 唐慧青, 瞿伟, 李亮, 钱珍, 顾坚忠, 徐平, 肖君华. BALB/cA.Cg.SHJH ^hr 小鼠的培育及其相关遗传学特性分析[J]. 实验动物与比较医学, 2023, 43(4): 363-370.
[12]	邓亚胜, 林江, 甘池伶, 曾官凤, 黄嘉茵, 邓慧芳, 麻颖贤, 韩丝银. 皮肤光老化动物模型制备要素和受试物数据的文献分析[J]. 实验动物与比较医学, 2023, 43(4): 406-414.
[13]	王雪, 呼永河. 糖尿病小鼠模型的常见种类及其构建要素分析[J]. 实验动物与比较医学, 2023, 43(4): 415-421.
[14]	黄慧, 邓亚胜, 梁天薇, 郑艺清, 范燕萍, 荣娜, 林江. 卵巢储备功能减退动物模型的造模方法评价与分析[J]. 实验动物与比较医学, 2023, 43(4): 422-428.
[15]	潘志强, 农淄心, 谢海纳, 彭佩克. 顺铂对小鼠下丘脑-垂体-肾上腺/性腺轴功能的损伤作用及脱氢表雄酮的干预效应[J]. 实验动物与比较医学, 2023, 43(3): 229-242.

复方卡森糖浆缓解D-氨基半乳糖引起的小鼠急性化学性肝损伤

Compound Casson Syrup Alleviates Acute Chemical Liver Injury in Mice Caused by D-galactosamine

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 4

参考文献 16

相关文章 15

编辑推荐

Metrics

本文评价